Friday, June 12, 2015

Weekly Links June 12th,2015



“MUST READ”
    • Irwin A. Rose, who shared the 2004 Nobel Prize in Chemistry with two collaborators for unraveling the mystery of how cells identify old and damaged proteins and transform them into pieces for new proteins — discoveries that led to the development of a new class of drugs to fight cancer — died on Tuesday in Deerfield, Mass. He was 88.

COMPANIES
    • That rhetoric may have to change, though, if Monsanto succeeds in buying its Swiss rival, pesticide giant Syngenta. On Friday, Syngenta's board rejected a $45 billion takeover bid. But that's hardly the end of the story. Tuesday afternoon, Syngenta's share price was holding steady at a level about 20 percent higher than it was before Monsanto's bid—an indication that investors consider an eventual deal quite possible. As The Wall Street Journal's Helen Thomas put it, the Syngenta board's initial rejection of Monsanto's overture may just be a way of saying, "This deal makes sense, but Syngenta can hold out for more."
  • Facebook Opens New AI Research Center In Paris | TechCrunch
    • France has many hidden gems, and Facebook is well-aware of that. The company is building a new artificial intelligence research team in Paris in order to work on ambitious futuristic projects. The new team will work closely with existing Facebook AI Research (FAIR) teams in Menlo Park and New York on image recognition, natural language processing, speech recognition, machine learning, live translating tools and more

SOMETHING DIFFERENT
    • The area of central Paris around rue du Sentier, once home to part of the garment district, is now home to a hive of innovation.
    • A decade ago, central Paris around Rue du Sentier — a warren of covered passageways, intimate squares and narrow cobbled streets with names like Cairo, Aboukir and Nile reflecting the area’s development during the Napoleonic campaigns — was an insider destination for cut-rate fashion and accessories in the city’s garment district. Lately, it has morphed into “Silicon Sentier”: a petri dish of entrepreneurial innovation that includes a tech incubator in an old factory as well as a digital arts center and bars where tech workers gather for custom cockta
  • Opus 23 – Music for a Gene d'Olivier Calmel: quand le gĂ©nome humain donne le la | Classicagenda

Monday, June 8, 2015

Weekly Links June 8th,2015



“MUST READ”
    • Big Genomics is converting hype to cash at unsettling speed. After the FDA told consumer genomics company 23andMe it could no longer sell people health data, the company began selling that data to drug and biotech companies. An entire industry, potentially fed by almost anyone who draws blood, spit, or biopsies from you, is emerging to do likewise. Its growth, along with the increasingly routine collection of genetic data by hospitals, will feed the genomics bubble while putting private genetic and health information at increased risk.
DISRUPTION, REVOLUTION
    • Scientists are developing ways to edit the DNA of tomorrow’s children. Should they stop before it’s too late?
TOOLS/TECHNIQUES
    • Amazon.com Inc is in a race against Google Inc to store data on human DNA, seeking both bragging rights in helping scientists make new medical discoveries and market share in a business that may be worth $1 billion a year by 2018.
Academic institutions and healthcare companies are picking sides between their cloud computing offerings - Google Genomics or Amazon Web Services - spurring the two to one-up each other as they win high-profile genomics business, according to interviews with researchers, industry consultants and analysts.
    • The introductory chapter has a very good history of Sanger sequencing. It discusses the NGS revolution, although I would not personally describe this as "currently under way" more like a pumpkin coloured tidal wave has washed over the world, and we're all waiting to see what happens next! The main technologies are explained in some detail, and the reviews are pretty much bang up to date. However 454 appears to be alive and kicking in this introduction - perhaps my bias as an Illumina user
HEALTH/MEDECINE
    • A new drug that unleashes the body’s immune system to attack tumors can prolong the lives of people with the most common form of lung cancer, doctors reported on Friday, the latest example of the significant results being achieved by this new class of medicines.
In a separate study, researchers said they had found that a particular genetic signature in the tumor can help predict which patients could benefit from the immune-boosting drugs.

COMPANIES
    • Genentech plans to make more than $2 billion in capital investments through 2016 in California, including lab expansions in South San Francisco and its manufacturing plants in Vacaville and Oceanside. It is building an "employee resource center," including a fitness center, and plans to construct a second child care center to hold another 500 children.
  • Any Given Cell: Can Biotech Pioneer Steve Fodor Do it Again? | Xconomy
  • About Us - Complete GenomicsComplete Genomics -
    • Complete Genomics is a leader in whole human genome sequencing based in Mountain View, California. Using its proprietary sequencing instruments, chemistry, and software, the company has sequenced more than 20,000 whole human genomes over the past five years. The company’s mission is to improve human health by providing researchers and clinicians with the core technology and commercial systems to understand, prevent, diagnose, and treat diseases and conditions.
  • Revolocity - Complete GenomicsComplete Genomics -
o    The Revolocity system is a complete solution for large-scale, high-quality whole genome sequencing (WGS) and whole exome sequencing (WES). 
        • Designed to sequence 10,000 WGS per year and expand to 30,000 WGS per year—surpassing the scalability of any other sequencing solution available today.
SOMETHING DIFFERENT
    • We have long known that men have a genetic, evolutionary impulse to cheat, because that increases the odds of having more of their offspring in the world.
But now there is intriguing new research showing that some women, too, are biologically inclined to wander, although not for clear evolutionary benefits.